SequelSEC

Opus Genetics, Inc. IRD

Pharmaceutical Preparations · CIK 0001228627 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$14.20M
Fiscal year ended 2025-12-31
Operating income
-$38.60M
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

Opus Genetics, Inc. (IRD) reported revenue of $14.20M and net income of -$49.59M for the fiscal year ended 2025-12-31. This page shows 7 annual periods of income statement, balance sheet and cash flow figures normalized from Opus Genetics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Opus Genetics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Revenue$14.20M$10.99M$19.05M$39.85M$589.00K$0$3.00M
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$38.60M-$62.07M-$10.56M$18.23M-$22.70M-$19.97M-$4.19M
Net income-$49.59M-$57.53M-$9.99M$17.89M-$56.69M-$24.62M-$6.17M
Research & developmentUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$5.48M
Weighted-average diluted sharesshares 62.22Mshares 26.72Mshares 21.59Mshares 20.60Mshares 14.85Mshares 4.66MUnavailable
Pretax income-$49.59M-$57.53M-$9.97M$18.20M-$56.69M-$24.62M-$6.17M
Income tax expense$0$0$12.00K$315.00K$0$0$0
Diluted EPS$-0.80$-2.15$-0.46$0.87$-3.82$-5.28Unavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$21.98M$18.22M$11.96M$7.27M$8.12M$2.82M$1.82M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Opus Genetics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Cash & equivalents$45.09M$30.32M$50.50M$42.63M$24.53MUnavailableUnavailable
Total assets$50.24M$36.86M$53.95M$48.99M$26.08M$17.68M$1.78M
Current assets$50.04M$36.61M$53.95M$48.99M$26.07M$17.67M$1.76M
Total liabilities$34.90M$11.30M$4.04M$2.75M$3.86M$31.15M$9.34M
Current liabilities$7.78M$11.30M$4.04M$2.75M$3.86M$3.18M$9.34M
Total equity incl. NCI$15.35M$6.72M$49.91M$46.24M$22.22M-$13.47M-$7.56M
Temporary (mezzanine) equity$0$0$0UnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivable$2.00M$3.56M$926.00K$1.30M$0$0Unavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt$1.13M$0UnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$3.29M$3.15M$2.15M$1.07M$1.58M$1.21M$342.00K

Cash flow

Opus Genetics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Operating cash flow-$35.25M-$25.58M-$1.11M$14.31M-$19.37M-$6.80M-$3.59M
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailable$0$25.00K
Investing cash flow$0$1.21M$0$0-$100.00K$539.00K-$25.00K
Financing cash flow$50.02M$4.19M$8.98M$3.79M$27.60M$21.12M$4.70M
Net change in cashUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Stock-based compensation$3.40M$3.36M$3.51M$1.81M$1.91M$1.51M$308.00K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$40.99K

Derived

Opus Genetics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable-$3.62M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating margin-271.9%-564.7%-55.5%45.7%-3854.8%UnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenue23.9%30.6%18.4%4.5%325.0%UnavailableUnavailable
Current ratio6.43x3.24x13.35x17.79x6.76x5.55x0.19x
Revenue YoY growth29.1%-42.3%-52.2%6665.7%Unavailable-100.0%Unavailable
Net margin-349.3%-523.4%-52.4%44.9%-9625.3%UnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable182.6%
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailable1.7%UnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open IRD in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-12View SEC filing
10-K · Filed 2026-03-12View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-13View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Reconciliation checks needing review

1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2024-12-31

Difference 18843000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.